Natural Capsules API first-half loss narrows to Rs 15.31 crore
Key highlights
- Natural Capsules reported an API first-half loss of Rs 15.31 crore, compared with Rs 15.58 crore a year earlier.
- API revenue was Rs 9.36 crore in the six months ended September 30, 2026, compared with Rs 2.18 crore a year earlier.
- The API segment's September-quarter loss was Rs 7.27 crore, versus Rs 8.04 crore in the June 2026 quarter.
- API capital employed was Rs 217.67 crore at September 30, 2026, compared with Rs 124.06 crore for Capsules.
powered by IRIS
Natural Capsules Limited reported an API segment loss of Rs 15.31 crore for the six months ended September 30, 2026, compared with a Rs 15.58 crore loss a year earlier, while API revenue rose to Rs 9.36 crore and the September-quarter loss was Rs 7.27 crore.
Know Natural Capsules inside out
Results, valuation, peers and who's buying, in one view.
How did the API segment perform in the first half?
Natural Capsules' API segment recorded a Rs 15.31 crore loss before tax and interest in the six months ended September 30, 2026, improving by Rs 0.27 crore from a Rs 15.58 crore loss in the corresponding six months of 2025. The segment result remained negative despite the narrower year-on-year loss.
API revenue rose to Rs 9.36 crore in the latest half year from Rs 2.18 crore a year earlier. Capsules segment profit before tax and interest increased to Rs 14.98 crore from Rs 9.99 crore, which helped total segment results move to a Rs 0.33 crore profit from a Rs 5.60 crore loss.
The first-half segment comparison sits alongside a consolidated loss before tax of Rs 10.42 crore for the six months ended September 30, 2026, versus a Rs 13.76 crore loss in the prior-year period. Interest expense was Rs 10.24 crore, compared with Rs 8.32 crore a year earlier, reducing the improvement in aggregate segment results.
What happened in the September 2026 quarter?
Natural Capsules' API segment posted a Rs 7.27 crore loss before tax and interest in the quarter ended September 30, 2026, compared with a Rs 8.04 crore loss in the June 2026 quarter. The Rs 0.77 crore sequential reduction meant the September quarter accounted for less than half of the Rs 15.31 crore first-half loss.
The year-on-year quarterly comparison remained adverse because API had reported a Rs 8.59 crore loss in the quarter ended September 30, 2025. API revenue was Rs 3.67 crore in the latest September quarter, compared with Rs 1.22 crore a year earlier, so the reported revenue increase did not produce a positive segment result.
Capsules produced Rs 7.88 crore of profit before tax and interest in the September 2026 quarter, against Rs 5.15 crore a year earlier. Total segment profit was therefore Rs 0.61 crore, compared with a Rs 3.45 crore total segment loss in September 2025; after Rs 5.27 crore of interest expense and Rs 0.08 crore of unallocable income, consolidated loss before tax was Rs 4.58 crore.
Got a follow-up? Ask IRIS
How much capital is employed in the API business?
Natural Capsules had Rs 217.67 crore of capital employed in the API segment at September 30, 2026, calculated in the filing as segment assets less segment liabilities. This was Rs 2.85 crore lower than the Rs 220.52 crore reported at March 31, 2026, but exceeded the Capsules segment's Rs 124.06 crore.
The API segment held Rs 240.67 crore of assets at September 30, 2026 and carried Rs 23.00 crore of liabilities. Capsules had Rs 181.07 crore of assets and Rs 57.91 crore of liabilities, resulting in lower capital employed despite Capsules generating Rs 47.48 crore of September-quarter revenue against API revenue of Rs 3.67 crore.
API represented Rs 217.67 crore of Natural Capsules' Rs 341.73 crore total segment capital employed at September 30, 2026. That capital base was paired with an API first-half loss of Rs 15.31 crore, while Capsules generated a Rs 14.98 crore first-half segment profit on Rs 124.06 crore of capital employed.
What does the segment split say about consolidated performance?
Natural Capsules generated consolidated revenue from operations of Rs 998.65 crore in the six months ended September 30, 2026, up from Rs 910.06 crore in the year-earlier period. Capsules supplied Rs 905.02 crore of that total, while API supplied Rs 9.36 crore, with the remaining difference arising from the reported segment total and the filing's presentation.
For the September 2026 quarter, consolidated revenue was Rs 51.15 crore, up from Rs 45.80 crore a year earlier and Rs 48.71 crore in the June 2026 quarter. Despite the quarterly revenue increase, Natural Capsules reported a Rs 4.58 crore consolidated loss before tax, reflecting Rs 5.27 crore of interest expense and the API segment's Rs 7.27 crore loss before tax and interest.
The filing reports a consolidated net loss after tax of Rs 9.97 crore for the six-month period, compared with a Rs 13.13 crore loss in the corresponding 2025 period. In the September quarter, consolidated net loss was Rs 2.24 crore after a Rs 5.74 crore loss in the June quarter, with the consolidated statement separately attributing results to shareholders and non-controlling interests.
Conclusion
Natural Capsules' September 2026 half-year disclosure shows a modest year-on-year reduction in the API segment loss, from Rs 15.58 crore to Rs 15.31 crore, alongside API revenue of Rs 9.36 crore. The segment nevertheless remained loss-making on Rs 217.67 crore of capital employed, while Capsules delivered Rs 14.98 crore of first-half segment profit.
The filing does not disclose a separate API turnaround target, investment plan or forecast. The unresolved matter is whether the sequential reduction in API loss from Rs 8.04 crore in June 2026 to Rs 7.27 crore in September 2026 continues in subsequent segment revenue, result and capital-employed disclosures.